Shandong Luoxin Phrm (SLUXF) 1.7267 $SLUXF
China Tropisetron (Novartis) Market Report 2015-2019
PR Newswire Europe - Thu Sep 03, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/97ztz9/investigation [http://www.researchandmarkets.com/research/97ztz9/investigation]) has announced the addition of the "Investigation Report on China Tropisetron Market, 2010-2019" [http://www.researchandmarkets.com/research/97ztz9/investigation] report to their offering.
NVS: 79.46 (+0.79)
Investigation Report on China's Tropisetron (Novartis) Market, 2010-2019
M2 - Thu Sep 03, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hwxdcr/investigation) has announced the addition of the "Investigation Report on China Tropisetron Market, 2010-2019" report to their offering. Tropisetron, developed by Novartis, entered the market in the Netherlands in 1992 and then the Chinese market in the late 1990s. Tropisetron got administrative protection authorized by the Chinese government in Mar. 1994 after its original developer Sandoz submitted application. But it is now a generic drug for its patent expired on Sep. 22, 2001. Tropisetron develops fast into the absolute leader antiemetics after entering China with annual sales rising from CNY 41 million in 2005 to CNY 600 million in 2014 and CAGR reaching up to 34.7% during the period of 2005- 2014. Currently, the tropisetron market in China is basically occupied by generic drugs which come from the following companies: Southwest Pharamceutical Co., Ltd, Wellso Pharmaceutical Co., Ltd, ReYoung Pharmaceutical Co., Ltd, Shandong Luoxin Pharmacy Stock Co., Ltd and Qilu Pharmaceutical Co., Ltd Tropisetron has big profit margins and is easy to be applied to clinics. Since there are hundreds of thousands of cancer patients undergoing chemoradiotherapy, tropisetron enjoys a promising market in China. Key Topics Covered: 1 Related Concepts of Tropisetron 2 Market Profile of Tropisetron in China 3 Survey on Sales Status of Tropisetron in China, 2010-2014 4 Survey on Market Share of Major Manufacturers of Tropisetron in China, 2010-2014 5 Survey on Dosage Forms of Tropisetron in China, 2010-2014 6 Reference Price of Tropisetron in Chinese Hospitals in 2014 7 Major Manufacturers of Tropisetron in Chinese Market, 2010-2014 8 Market Outlook of Tropisetron in China, 2015-2019 Companies Mentioned - Qilu Pharmaceutical Co., Ltd - ReYoung Pharmaceutical Co., Ltd - Shandong Luoxin Pharmacy Stock Co., Ltd - Southwest Pharamceutical Co., Ltd - Wellso Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/hw...estigation
NVS: 79.46 (+0.79)
Investigation Report on China's Cefathiamidine Market, 2010-2019
M2 - Thu Aug 06, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bg8zn7/investigation) has announced the addition of the "Investigation Report on China's Cefathiamidine Market, 2010-2019" report to their offering. Developed by Guangzhou Baiyunshan Pharmaceutical General Factory, cefathiamidine has been written into the Chinese Pharmacopoeia (2005). Ever since its marketing in 2000, the sales value of cefathiamidine has risen from less than CNY 100 million in 2005 to CNY 459 million in 2014 with CAGR during this period reaching up to 18.6%. Despite its status as the first generation of cephalosporin, cefathiamidine's antimicrobial effect especially that on enterococcus has surpassed all other similar products. As a mature product in the clinic, cefathiamidine has been widely used for the treatment of respiratory, liver, five senses, urinary tract infections, endocarditis and sepsis. Manufacturers of cefathiamidine focus on high-end market and emphasize products' ingenuity and outstanding quality. Currently, the cefathiamidine industry shows a high degree of market concentration. We have Guangzhou Baiyunshan Pharmaceutical General Factory, Shandong Luoxin Pharmacy Stock Co., Ltd, Shandong Lukang Pharmaceutical Co., Ltd, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd and Fuan Pharmaceutical (Group) Qingyutang Pharmaceutical Co., Ltd, among which Guangzhou Baiyunshan Pharmaceutical General Factory has the largest market share of 82.33% in 2014 for sales value. As cefathiamidine acts like Methicillin-resistant Staphylococcus aureus (MRSA) and is much safer than traditional drugs for MRSA like vancomycin, norvancomycin, teicoplanin and linezolid, it still has a market potential. The market size of cefathiamidine is expected to keep growing in the next few years in China. Key Topics Covered: 1 Related Concepts of Cefathiamidine 2 Market Profile of Cefathiamidine in China 3 Survey on Sales Status of Cefathiamidine in China, 2010-2014 4 Survey on Market Share of Major Manufacturers of Cefathiamidine in China, 2010-2014 5 Survey on Dosage Forms of Cefathiamidine in China, 2010-2014 6 Reference Price of Cefathiamidine in Chinese Hospitals in 2014 7 Major Manufacturers of Cefathiamidine in Chinese Market, 2010-2014 8 Market Outlook of Cefathiamidine in China, 2015-2019 Companies Mentioned - Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. - Baiyunshan Pharmaceutical General Factory - Shandong Luoxin Pharmacy Stock Co., Ltd - Shandong Lukang Pharmaceutical Co., Ltd - Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd - Fuan Pharmaceutical (Group) Qingyutang Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/bg...estigation
China Tropisetron (Novartis) Market Report 2015-2019
PR Newswire Europe - Thu Sep 03, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/97ztz9/investigation [http://www.researchandmarkets.com/research/97ztz9/investigation]) has announced the addition of the "Investigation Report on China Tropisetron Market, 2010-2019" [http://www.researchandmarkets.com/research/97ztz9/investigation] report to their offering.
NVS: 79.46 (+0.79)
Investigation Report on China's Tropisetron (Novartis) Market, 2010-2019
M2 - Thu Sep 03, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hwxdcr/investigation) has announced the addition of the "Investigation Report on China Tropisetron Market, 2010-2019" report to their offering. Tropisetron, developed by Novartis, entered the market in the Netherlands in 1992 and then the Chinese market in the late 1990s. Tropisetron got administrative protection authorized by the Chinese government in Mar. 1994 after its original developer Sandoz submitted application. But it is now a generic drug for its patent expired on Sep. 22, 2001. Tropisetron develops fast into the absolute leader antiemetics after entering China with annual sales rising from CNY 41 million in 2005 to CNY 600 million in 2014 and CAGR reaching up to 34.7% during the period of 2005- 2014. Currently, the tropisetron market in China is basically occupied by generic drugs which come from the following companies: Southwest Pharamceutical Co., Ltd, Wellso Pharmaceutical Co., Ltd, ReYoung Pharmaceutical Co., Ltd, Shandong Luoxin Pharmacy Stock Co., Ltd and Qilu Pharmaceutical Co., Ltd Tropisetron has big profit margins and is easy to be applied to clinics. Since there are hundreds of thousands of cancer patients undergoing chemoradiotherapy, tropisetron enjoys a promising market in China. Key Topics Covered: 1 Related Concepts of Tropisetron 2 Market Profile of Tropisetron in China 3 Survey on Sales Status of Tropisetron in China, 2010-2014 4 Survey on Market Share of Major Manufacturers of Tropisetron in China, 2010-2014 5 Survey on Dosage Forms of Tropisetron in China, 2010-2014 6 Reference Price of Tropisetron in Chinese Hospitals in 2014 7 Major Manufacturers of Tropisetron in Chinese Market, 2010-2014 8 Market Outlook of Tropisetron in China, 2015-2019 Companies Mentioned - Qilu Pharmaceutical Co., Ltd - ReYoung Pharmaceutical Co., Ltd - Shandong Luoxin Pharmacy Stock Co., Ltd - Southwest Pharamceutical Co., Ltd - Wellso Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/hw...estigation
NVS: 79.46 (+0.79)
Investigation Report on China's Cefathiamidine Market, 2010-2019
M2 - Thu Aug 06, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bg8zn7/investigation) has announced the addition of the "Investigation Report on China's Cefathiamidine Market, 2010-2019" report to their offering. Developed by Guangzhou Baiyunshan Pharmaceutical General Factory, cefathiamidine has been written into the Chinese Pharmacopoeia (2005). Ever since its marketing in 2000, the sales value of cefathiamidine has risen from less than CNY 100 million in 2005 to CNY 459 million in 2014 with CAGR during this period reaching up to 18.6%. Despite its status as the first generation of cephalosporin, cefathiamidine's antimicrobial effect especially that on enterococcus has surpassed all other similar products. As a mature product in the clinic, cefathiamidine has been widely used for the treatment of respiratory, liver, five senses, urinary tract infections, endocarditis and sepsis. Manufacturers of cefathiamidine focus on high-end market and emphasize products' ingenuity and outstanding quality. Currently, the cefathiamidine industry shows a high degree of market concentration. We have Guangzhou Baiyunshan Pharmaceutical General Factory, Shandong Luoxin Pharmacy Stock Co., Ltd, Shandong Lukang Pharmaceutical Co., Ltd, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd and Fuan Pharmaceutical (Group) Qingyutang Pharmaceutical Co., Ltd, among which Guangzhou Baiyunshan Pharmaceutical General Factory has the largest market share of 82.33% in 2014 for sales value. As cefathiamidine acts like Methicillin-resistant Staphylococcus aureus (MRSA) and is much safer than traditional drugs for MRSA like vancomycin, norvancomycin, teicoplanin and linezolid, it still has a market potential. The market size of cefathiamidine is expected to keep growing in the next few years in China. Key Topics Covered: 1 Related Concepts of Cefathiamidine 2 Market Profile of Cefathiamidine in China 3 Survey on Sales Status of Cefathiamidine in China, 2010-2014 4 Survey on Market Share of Major Manufacturers of Cefathiamidine in China, 2010-2014 5 Survey on Dosage Forms of Cefathiamidine in China, 2010-2014 6 Reference Price of Cefathiamidine in Chinese Hospitals in 2014 7 Major Manufacturers of Cefathiamidine in Chinese Market, 2010-2014 8 Market Outlook of Cefathiamidine in China, 2015-2019 Companies Mentioned - Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. - Baiyunshan Pharmaceutical General Factory - Shandong Luoxin Pharmacy Stock Co., Ltd - Shandong Lukang Pharmaceutical Co., Ltd - Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd - Fuan Pharmaceutical (Group) Qingyutang Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/bg...estigation
